PCVX

PCVX EBITDA Growth

-116.15%TTM

Period ending:

PCVX TTM EBITDA YoY %%
PCVX TTM EBITDA YoY %22.49%-133.42%
2020-12-312026-06-30

Source: Financial Modeling Prep (FMP). Trailing twelve months (TTM). TTM flows use four complete reported quarters. Growth compares with the corresponding period one year earlier.

PCVX ebitda growth history

Year-over-year EBITDA growth rate. The available trailing twelve months (ttm) series contains 23 observations from Dec 31, 2020 to Jun 30, 2026.

Vaxcyte Inc EBITDA Growth — Trailing twelve months (TTM)
Period endingEBITDA Growth
-116.1527%
-105.1512%
-83.2105%
-5.1853%
3.7243%
2.6429%
7.4022%
-58.1899%
-78.8251%
-87.4883%
-103.9713%
-101.9257%
-106.9482%
-118.3302%
-117.5469%
-81.2205%
-57.3998%
-34.5907%
-12.2214%
-12.1226%
-20.1414%
-34.0973%
-79.1646%

Compare ebitda growth

All PCVX financial metrics · PCVX stock overview · How to interpret financial metrics

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.